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Introduction
Worldwide emergence of multi-and extensively drug-resistant tuberculosis (MDR and XDR-TB) has become a major obstacle to TB control. XDR-TB is a form of TB caused by Mycobacterium tuberculosis (MTB) strains, which is resistant to isoniazid (INH) and rifampicin (RIF), defined as multidrug-resistant MTB (MDR-MTB), as well as fluoroquinolone (FQ) and any of the second-line anti-TB injectable drugs, amikacin (AMK), kanamycin (KAN), or capreomycin (CAP). By the end of 2010, 68 countries had reported at least one case of XDR-TB. 1 XDR-TB is the result of an adverse treatment outcome of MDR-TB; many cases are never diagnosed due to limitations in laboratory capacity to test for second-line drug resistance. 2 Treatment of XDR-TB patients is more challenging and less successful than that of patients with other types of TB. 3 An extremely high death rate from XDR-TB was reported in patients co-infected with HIV in South Africa. 2, 4 In Nepal, TB is a major public health problem. The incidence of all forms of TB was estimated to be 173/100,000 population while the incidence of new smear-positive cases estimate of MDR-TB is 2.9% and 11.7% among new and recurrent cases, respectively. 1, 5, 6 Although the prevalence of drug-resistance confirming mutations in MDR-TB isolates in Nepal have been reported recently, 6 to the best of our knowledge, no published data on mutations and genotypes of XDR-MTB strains are currently available from Nepal.
Molecular epidemiological studies of M. tuberculosis strains have identified variability in the phylogeography of strains globally. 7, 8 Beijing strains are most prevalent globally and also associated with enhanced acquisition of drug resistance; however their resistance patterns varied regionally. 9 Drug resistance in M. tuberculosis is commonly caused by mutations in various genes. Previous works have indicated that mutations within 81-bp core region of the RNA polymerase β-subunit gene (rpoB) gene are the cause of RIF resistance in more than 90% of cases. 10, 11 In contrast, several different loci are known to be involved in INH resistance, especially katG and inhA. 6, 10 Mutations in a conserved quinolone resistance-determining region (QRDR) of the gyrA or gyrB genes encoding DNA gyrase are often involved in fluoroquinolone (FQ) resistance. 12 
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Resistance to aminoglycosides (KAN and AMK) and CAP is attributed to mutations in 16s rRNA (rrs) gene.
13, 14
The present study documents drug resistance-associated mutations in XDR isolates from Nepal. To gain an insight into the epidemiology of these isolates, genotyping by using spoligotyping, multilocus sequence typing (MLST) and variable number of tandem repeats (VNTR) were also performed.
Materials and methods

M. tuberculosis isolates
A total of 109 MDR M. tuberculosis clinical isolates were randomly selected from isolates bank at German Nepal Tuberculosis Project (GENETUP), Nepal, collected over a 3-year period from 2007 to 2010. Each isolates were recovered from individual patients with pulmonary TB.
Antibiotic susceptibility testing
Testing for susceptibility to first-and second-line drugs was carried out at GENETUP using the conventional proportional method on Löwenstein-Jensen medium according to the World Health Organization guidelines 15 
DNA extaction
DNA was prepared for PCR by mechanical disruption, as described previously. 6 Briefly, the colonies were suspended in TE buffer consisting of 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA in a 2 ml screw-cap vial, one-fourth of which was filled with 0.5 g glass beads (0.1 mm) (Bio Spec Products Inc., Bartlesville, OK). Mycobacterial cells were disrupted by shaking with 0.5 ml chloroform on a cell disrupter (Micro smash; Tomy Seiko Co. Ltd., Tokyo, Japan) for 1 min. After centrifugation, the DNA in the upper layer was concentrated by ethanol precipitation and dissolved in 100 µl TE buffer.
PCR amplification and DNA sequencing of drug resistance-associated genes
PCR reactions were performed in a 20 µl mixture consisted of 0.25 mM each of dNTPs, 0.5 M betaine, 0.5 µM of each primer (Primers for rrs, gyrA and gyrB in Table 1 and those in Poudel A et al. 6 for rpoB, katG and inhA gene segment amplification 
Phylogenetic markers
Spoligotyping was performed according to the standard protocol. 16 and the spoligotype in the binary format was compared with the SpolDB4 database. 17 Another molecular epidemiological investigation was performed by PCR amplification of the 26 variable M.
tuberculosis microsatellites and assigned an allele number based on the number of repeats as described previously. 18 A combined spoligotype-VNTR UPGMA3
dendrogram was computed and drawn using Bionumerics 6.0 version software (Applied 
Results
Drug-susceptibility patterns
Among 109 MDR-MTB isolates obtained, 13 were found to be XDR ( Table 2) . Three of the patients having XDR-TBs (84, 90 and 123) were naive for MDR treatment. Of the remaining 96 isolates, 41, 1, and 1 were mono-resistant to OFX, KAN, and CAP, respectively, and categorized as pre-XDR-MTB.
Geographical distribution of XDR M.tuberculosis isolates
The XDR-MTB isolates were originated from patients living in five main cities of Nepal ( Figure 1 ): Kathmandu (n = 7), Pokhara (n = 3), Butwal (n = 1), Bhairahawa (n = 1) and Dhangadhi (n = 1). The number of XDR-TB in Kathmandu correlates well with its high population.
Mutations identified in the rpoB, katG, inhA, gyrA, gyrB and rrs genes
Sequence analysis identified the most frequent mutations conferring Ser to Leu amino acid substitution at position 531 (Ser531Leu) in rpoB (12/13), Ser315Thr in katG 5 (12/13), Asp94Gly in gyrA (7/13), and a mutation from A to G at nucleotide position 1400 (A1400G) in rrs (9/13). Other mutations with lower rates were seen in rpoB (Asp516Val; 1/13), inhA regulatory region (C-15T; 1/13), gyrA (Ser91Pro; 1/13, Asp94Ala; 2/13, Asp94Asn; 1/13, Asp94His; 1/13, and Asp94Tyr; 1/13), and rrs (C1401T and G1483T; two each), while none had mutations in the quinolone resistancedetermining region of gyrB (Table 2) .
Spoligotyping and MLST
Among XDR-TB isolates, Spoligotyping revealed the predominance of Beijing family strains (9/13). In addition, 1 strain of CAS family, 2 strains of T family (T1 and T2) and 1 strain of undefined type were also identified. MLST confirmed 8 isolates with Bejing spoligotype belonged to modern types ( Table 2) .
Cluster analysis by VNTR
VNTR typing grouped the isolates into seven unique patterns and two clusters ( for KAN/CAP resistance).
Discussion
In this study, we investigated drug resistance-associated mutations and genotypes of XDR-MTB isolates in Nepal. This study also raises concerns over the high proportion of pre-XDR-TB in Nepal. The high rate of pre-XDR-MTB isolates implied the inappropriate usage of drugs, especially FQs, including OFX. OFX is the most commonly prescribed antibiotic for respiratory tract infection in Nepal and this might lead to the emergence of pre-XDR-TB with resistance to OFX. As drug resistance in M.
tuberculosis is due to the stepwise accumulation of mutations in the genome, this pool of pre-XDR-MTB isolates are always at the risk of developing XDR-TB. the Beijing family, known to have higher mutation-acquiring capacity. The high number of MDR-TB patients who stop treatment in Nepal could also explain this high drug resistance acquisition rate. 5 Both the possibility of direct transmission and acquired resistance should be considered equally for XDR-TB in Nepal.
Conclusion
The majority of XDR-MTB isolates in this study belonged to the Beijing family.
Infections of this family were more common among younger generation than those belonging to other spoligotype families. In addition, the identical pattern of VNTR and 
